Evidence map›Paper›PMID 36851129›Full record

ReviewVaccines2023

Tilapia Lake Virus Vaccine Development: A Review on the Recent Advances.

Japhette E Kembou-Ringert, Dieter Steinhagen, John Readman, Janet M Daly, Mikolaj Adamek

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Vaccines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
6.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 39 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Frontiers in microbiology · 2025
    Article
  9. Article
  10. Review
  11. Article
  12. Current Challenges of Vaccination in Fish Health Management.Animals : an open access journal from MDPI · 2024
    Review
  13. Article
  14. A New Cell Line from the Brain of Red Hybrid Tilapia (Animals : an open access journal from MDPI · 2024
    Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Japhette E Kembou-RingertDepartment of Infection, Immunity and Inflammation, Great Ormond Street Institute of Child Health, University College London, 30 Guilford Street, London WC1N 1EH, UK.ORCID 0000-0002-9612-7799
Dieter SteinhagenFish Disease Research Unit, Institute for Parasitology, University of Veterinary Medicine Hannover, Buenteweg 17, 30559 Hannover, Germany.ORCID 0000-0002-2303-8533
John ReadmanDepartment of Infection, Immunity and Inflammation, Great Ormond Street Institute of Child Health, University College London, 30 Guilford Street, London WC1N 1EH, UK.
Janet M DalySchool of Veterinary Medicine and Science, University of Nottingham, Sutton Bonington LE12 5RD, UK.ORCID 0000-0002-1912-4500
Mikolaj AdamekFish Disease Research Unit, Institute for Parasitology, University of Veterinary Medicine Hannover, Buenteweg 17, 30559 Hannover, Germany.ORCID 0000-0003-4890-3164
University College London · GBUniversity of Veterinary Medicine Hannover, Foundation · DEUniversity of Nottingham · GB

Funding

Deutsche Forschungsgemeinschaft 426513195Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) - "Open Ac-cess Publication Funding" and the University of Veterinary Medicine Hannover, Foundation 491094227National Institute of Health Research (NIHR) - Great Ormond Street Hospital Biomedical Re-search Centre (GOSH-BRC) [NIHR - GOSH-BRC] #20IA27
6 · The paper itself

Abstract

Tilapia tilapinevirus (or tilapia lake virus, TiLV) is a recently emerging virus associated with a novel disease affecting and decimating tilapia populations around the world. Since its initial identification, TiLV has been reported in 17 countries, often causing mortalities as high as 90% in the affected populations. To date, no therapeutics or commercial vaccines exist for TiLV disease control. Tilapia exposed to TiLV can develop protective immunity, suggesting that vaccination is achievable. Given the important role of vaccination in fish farming, several vaccine strategies are currently being explored and put forward against TiLV but, a comprehensive overview on the efficacy of these platforms is lacking. We here present these approaches in relation with previously developed fish vaccines and discuss their efficacy, vaccine administration routes, and the various factors that can impact vaccine efficacy. The overall recent advances in TiLV vaccine development show different but promising levels of protection. The field is however hampered by the lack of knowledge of the biology of TiLV, notably the function of its genes. Further research and the incorporation of several approaches including prime-boost vaccine regimens, codon optimization, or reverse vaccinology would be beneficial to increase the effectiveness of vaccines targeting TiLV and are further discussed in this review.

Indexed as

fish vaccinetilapia lake virusvaccinationvaccines in aquaculture

Identifiers

PMID36851129
PMCPMC9961428
OpenAlexW4317738341

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.